On the stock market since 2017, it operates in the world of health and science. It has 61 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Average growth of 28% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly above the class average — a step short of the very top.
The cash pile is strong; debt and other items pull the grade toward the middle.
Clearly above the class average — a step short of the very top.
Sales are growing strongly for its sector.
The price is looking for direction — no strong breakout, no collapse.
No real weak spot in any of the five subjects — a balanced report card.
An investor who bought at the very peak is down 67% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 3 years, sales grew about 37% a year on average.
Sales run at $24.0M a year. A small number, but proof the product has real buyers.
There is $6.0M in the vault; even if every debt were paid off, $2.4M would remain.
A loss of $363K against $24.0M in annual sales.
No clear buy-side message is coming from the executive floor.
On our five-subject report card, PRPO sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: PRPO is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.